Introduction
Hepatic transport plays an important role in the pharmacokinetics and pharmacodynamics of rosuvastatin (RSV) because the liver is the target organ for pharmacologic activity as well as the primary organ of elimination. Hepatic clearance accounts for 72% of total RSV clearance following an intravenous dose in humans . A number of transport proteins mediating RSV disposition in the liver have been characterized. Active uptake into hepatocytes is facilitated by multiple OATP isoforms; NTCP also has been reported to play a role (Ho et al., 2006; Abe et al., 2008; Kitamura et al., 2008) . MRP2 and BCRP are the canalicular proteins primarily responsible for RSV biliary excretion Kitamura et al., 2008; Keskitalo et al., 2009; Jemnitz et al., 2010; Hobbs et al., 2012) . The role of basolateral transport proteins in RSV efflux from hepatocytes back into sinusoidal blood has not been examined. Hepatic basolateral efflux of RSV could be clinically relevant because impaired hepatic transport due to drug-drug interactions (DDIs) and genetic polymorphisms has been shown to alter the pharmacokinetics of RSV Simonson et al., 2004; Zhang et al., 2006; Kiser et al., 2008; Kitamura et al., 2008; Keskitalo et al., 2009; Hobbs et al., 2012) . Some of these changes have been associated with altered efficacy (LDL-lowering) of RSV (Simonson et al., 2003; Tomlinson et al., 2010) , while increased systemic exposure has been associated with life-threatening rhabdomyolysis, which is related to statin use in general (Hamilton-Craig, 2001 ; Thompson et al., 2003) .
Candidate basolateral efflux transporters for RSV include MRP3 and MR4, which mediate hepatic basolateral excretion of drugs and metabolites, particularly as a compensatory route of excretion under cholestatic conditions (Scheffer et al., 2002; Denk et al., 2004; Gradhand et al., 2008; Chai et al., 2012) . vitro clearance for uptake (CL Uptake ) and/or biliary excretion (CL Bile ), which can be used to predict in vivo clearance values based on scaling factors such as protein content and hepatocellularity (Swift et al., 2010a) . Less frequently, the SCH model has been employed to assess efflux by preloading cells with substrates (± inhibitors), followed by an efflux phase, and quantifying substrate in cells+bile, cells and/or appearance in buffer (Jemnitz et al., 2010; Swift et al., 2010b) . However, the SCH system has not been characterized under these conditions. In a "simplified" conception of the SCH system, maintenance of tight junctions in the presence of Ca 2+ would completely seal the bile networks, and efflux experiments would reflect only basolateral efflux clearance (CL BL ) (Fig. 1) . Efflux in the absence of Ca 2+ with disrupted tight junctions would reflect basolateral plus biliary efflux, and would be greater than efflux in the presence of Ca 2+ ( Fig. 1 , hepatocyte scheme). In reality, the SCH model is dynamic, with regular and extensive "pulsing" of the bile canaliculi, similar to reports in hepatocyte couplets and cultured hepatocytes (Boyer et al., 1988; Shinoda et al., 1998) (Fig. 1) . Thus, appearance of substrate in buffer in the presence of Ca 2+ reflects CL BL plus periodic flux of accumulated substrate within the bile spaces (K Flux ). In order to deconvolute these data and elucidate the contributions of CL Uptake , CL Bile , CL BL and K Flux , a pharmacokinetic modeling approach can be applied to SCH data (Liu et al., 1999; Hoffmaster et al., 2005; Lee et al., 2010; Yang and Brouwer, 2012; Pfeifer and Brouwer, 2013) .
The purpose of the present studies first was to determine appropriate conditions for conducting efflux studies in the SCH system. A novel uptake/efflux protocol was developed to determine RSV disposition in rat and human SCH. This method, combined with pharmacokinetic (PK) modeling, revealed that basolateral and biliary clearance represent alternative elimination routes with a quantitatively similar contribution to the overall hepatocellular excretion of RSV in rat and human SCH.
The role and influence of certain transporters in the basolateral and canalicular (biliary) efflux of RSV was explored in the SCH system, as well as isolated expression systems.
This article has not been copyedited and formatted. The final version may differ from this version. Preliminary studies were performed to optimize the uptake/efflux protocol and evaluate tight junction modulation using two potential schemes for conducting efflux studies in SCH under Ca 2+ -free conditions: (Fig. 1Aii) pre-incubation and uptake exclusively in standard (+Ca 2+ ) HBSS, followed by a brief wash and efflux in Ca 2+ -free HBSS, or ( Fig. 1A. iii) maintaining open tight junctions throughout the study period by pre-incubating in Ca 2+ -free HBSS, then performing an uptake phase in standard HBSS (<30 min) to provide relief from the removal of Ca 2+ , followed by a brief wash and efflux in Ca 2+ -free
HBSS.
The uptake/efflux protocol described in Fig. 1A was characterized using 1 μ M carboxydichlorofluorescein diacetate (CDFDA), and fluorescence intensity in bile networks was observed by serial imaging using a Zeiss Axiovert 100TV inverted fluorescent microscope (Carl Zeiss Inc., Thornwood, NY) as depicted in Fig. 1B .
For uptake and efflux studies with RSV, SCH were treated with 0.1 or 1 μ M [ 3 H]RSV (100 nCi/mL) in the absence or presence of GF120918 (0.5 μ M) in standard HBSS for 20 min at 37°C. After the 20-min uptake phase, buffers containing RSV were removed, cells were washed twice with 37°C standard or Ca 2+ -free HBSS buffer without RSV, and the third application of buffer was added to SCH for the 15-min efflux phase (Fig. 1A) . For conditions in the presence of inhibitor, 0.5 μ M GF120918 was maintained in the incubation buffer for the duration of the experiment (pre-incubation, uptake and efflux phases). Preliminary studies indicated that 0.5 µM GF120918 was sufficient to inhibit RSV biliary excretion in SCH with minimal impact on uptake. RSV accumulation in cells+bile, cells, and medium (standard HBSS or Ca 2+ -free HBSS buffer) during uptake (2, 5, 10, and 20 min) and efflux (2, 5, 10, and 15 min) phases were determined by terminal sampling of n=3 wells at each time point. In all cases, incubation medium was collected at the end of the incubation period, and cells were washed twice in icecold HBSS. Cells were solubilized in 0.3 mL 0.5% Triton X-100 and radioactivity in cell lysates and 
Pharmacokinetic Modeling
Pharmacokinetic modeling and simulation were used to evaluate RSV disposition in SCH studies, and to determine the effects of GF120918 and loss of Mrp2 function on RSV hepatobiliary disposition in rat SCH. A model scheme incorporating linear parameters governing RSV flux ( 
Mass in buffer (Ca 2+ -free HBSS):
Mass in cells:
Mass in bile (Standard HBSS): 
Membrane Vesicles
Human MRP3 plasmid (pcNDA3.1(-)-MRP3) and MRP4 plasmid (pcDNA3.1(-)-MRP4) were kindly provided by Dr. Susan Cole (Queen's University, Kingston, Canada) and Dr. Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany), respectively. Transiently transfected HEK293T cells were generated and membrane vesicles were prepared as described previously (Leslie et al., 2001) . Transport experiments were carried out by a rapid filtration assay as described previously (Ghibellini et al., 2008) . Briefly, membrane vesicles (10 μ g protein) were incubated at 37°C with test compound in Tris-sucrose buffer (TSB; 50 mM Tris-HCl, 250 mM sucrose, 10 mM MgCl 2 , 10 mM creatine phosphate, 100 μ g/mL creatine kinase, 4 mM ATP or AMP) and 20 is presented as ATP-dependent uptake, after subtracting endogenous ATP-dependent uptake in NT vesicles. All data are expressed as mean±SD of triplicate determinations in a single experiment.
Data Analysis
The effect 
Results

SCH
Preliminary studies conducted to evaluate tight junction modulation and to optimize the uptake/efflux protocol are shown in Fig. 1 1Biii) . In contrast, disappearance of CDF fluorescence intensity in bile networks after switching from standard HBSS to Ca 2+ -free HBSS at the wash phase, suggested a time frame of ~5 min for opening of bile networks ( Fig. 1Bii Efflux Phase in Ca 2+ -free HBSS). As a measure of cell viability during the uptake/efflux protocol, less than 4% and 7% of total cellular LDH content was released over the 35-min experimental time course in both rat and human SCH, respectively, as shown in Fig. 2 .
The mass-time profiles of RSV in cells+bile, cells and buffer during the optimized uptake/efflux protocol described in Fig Parameter estimates recovered from fitting differential equations based on the model scheme in Fig. 3simultaneously to data at both 0.1 and 1 uM concentrations from independent SCH preparations are listed in Uptake of 1 µM RSV and subsequent efflux was examined in SCH from three human liver preparations (Fig. 4) . Parameter estimates recovered from fitting the differential equations based on the model scheme depicted in Fig. 3 to data from independent human SCH preparations are listed in Table 1. CL Uptake was at least an order of magnitude greater than the efflux pathways (CL BL and CL Bile) ), which were of similar magnitude; CL BL was approximately 3-fold greater than CL Bile . K Flux was similar to the value observed in rat SCH.
Sensitivity Analysis
Sensitivity analysis of parameter estimates on model output was conducted, with resulting changes in simulated cellular accumulation and efflux into buffer shown in Fig. 6 . Cellular accumulation at the end of the uptake phase was most sensitive to CL Uptake in the absence and presence of Ca 2+ . 
MRP3-and MRP4-Mediated Transport in Membrane Vesicles
This article has not been copyedited and formatted. The final version may differ from this version. The inhibitory potential and substrate specificity of RSV for MRP3 and MRP4 was evaluated using membrane vesicles prepared from non-transfected (NT) and MRP-overexpressing HEK293T cells.
Pilot studies confirmed ATP-dependent uptake was linear up to 5 and 2 min for the prototypical MRP3
and MRP4 probe substrates, E 2 17G and DHEAS, respectively (data not shown). ATP-dependent uptake determined at 1 min was concentration-dependent with a K m and V max of 23±5 µM and 1700±200
pmol/min/mg protein, respectively, for E 2 17G, and 2.9±0.2 µM and 390±40 pmol/min/mg protein, respectively, for DHEAS (mean±SD). Co-incubation with 50 µM RSV inhibited ATP-dependent transport of the prototypical MRP3 and MRP4 probe substrates, E 2 17G (20 µM) and DHEAS (2 µM), by 76±2 and 88±5%, respectively ( Fig. 7A and B) . By comparison, ATP-dependent transport of E 2 17G (20 µM) and DHEAS (2 µM) was 77±3 and 88±5% lower in NT membrane vesicles, and decreased by 98±2
and 105±3% in the presence of the potent pan-MRP inhibitor, MK571 (50 µM, Fig. 7A and B). ATPdependent transport of 0.1 µM RSV was linear up to ~1 min, and was greater in membrane vesicles from HEK293T cells overexpressing MRP4 and MRP3 compared to NT cells (Fig. 7C) . Uptake of RSV at 1 min in membrane vesicles from MRP4-overexpressing cells was concentration-dependent with a K m and V max of 21±7 µM and 1140±210 pmol/min/mg protein for MRP4 (Fig. 7D) . Despite inhibition of MRP3-mediated E 2 17G transport by 50 µM RSV (Fig. 7A) , and apparent MRP3-dependent RSV uptake at low concentrations ( Fig. 7C) , ATP-dependent uptake of RSV over a range of concentrations in membrane vesicles from MRP3-overexpressing cells was not significantly greater than uptake into vesicles prepared from NT cells (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. . One is to pre-incubate and perform the uptake phase in standard (+Ca 2+ )
HBSS, followed by a brief wash and efflux in Ca 2+ -free HBSS (Fig. 1Aii ) (Jemnitz et al., 2010; Swift et al., 2010b) . A limitation of this approach is that substrate accumulation in bile networks during the uptake phase may not be washed away completely before initiating the efflux phase in Ca 2+ -free HBSS.
Based on the disappearance of CDF fluorescence intensity in bile networks ( Fig. 1Bii Efflux Phase), the time required for complete opening of canalicular networks is 2-5 min. Prior to this time, efflux into the buffer in Ca 2+ -free HBSS reflects, in part, content from the opening of bile networks. Another potential design for efflux studies involves maintaining open tight junctions throughout the study period. This is accomplished by pre-incubating in Ca 2+ -free HBSS, and then performing the uptake phase in standard HBSS to provide relief from prolonged exposure to Ca 2+ -free conditions, followed by a brief wash and efflux in Ca 2+ -free HBSS (Fig. 1Aiii) . A limitation with this method is potential re-sealing of the tight junctions during Ca 2+ repletion throughout the uptake phase (Liu et al., 1999) . However, imaging with CDF suggests that re-sealing of the tight junctions allowing substrate accumulation in the bile networks is minimal over the 20-min uptake phase (Fig. 1Biii) . Therefore, based on the data generated, preincubating SCH in standard or Ca 2+ -free HBSS prior to performing the uptake phase in standard HBSS, followed by a brief wash and then efflux in standard or Ca 2+ -free HBSS [ Fig. 1 (Swift et al., 2010a) . In the present study, less than 4 and 7% of total cellular LDH content was released over the 35-min uptake/efflux protocol in rat and human SCH, respectively (Fig. 2) .
RSV cellular accumulation and appearance in buffer were simulated to reflect 10-fold changes in parameter estimates describing RSV disposition in rat SCH (Table 1 ; WT Control). The simulated data reported in Fig. 6 include RSV accumulation in cells+bile and cells at the end of the 20-min uptake phase, as well as the mass of RSV in buffer at the end of the 15-min efflux phase. As expected, the simulated data were least sensitive to changes in the K Flux parameter, which was estimated solely from standard HBSS conditions because this process is absent in Ca 2+ -free conditions. Cellular accumulation at the end of the uptake phase was most sensitive to CL Uptake . The amount of substrate in buffer at the end of the efflux phase was most sensitive to increased CL Bile and CL BL in Ca 2+ -free HBSS, while efflux in standard HBSS was most sensitive to CL Uptake values, but also to increased CL BL . Interestingly, efflux into buffer was inversely proportional to CL BL , and also CL Bile in Ca 2+ -free HBSS. This may seem paradoxical until one considers that greater efflux will decrease cellular accumulation during the uptake phase, which drives substrate appearance in buffer during the efflux phase. These findings illustrate the power of a modeling and simulation approach to analyze and interpret the data, and to further characterize and understand the SCH system under conditions used to perform efflux studies.
SCH data, combined with pharmacokinetic modeling, revealed that CL BL and CL Bile represent alternative pathways with a quantitatively similar contribution to the total hepatocellular excretion of RSV under normal conditions in rat and human SCH. The effects of modulating Mrp2 and Bcrp function using TR -SCH and GF120918, respectively, were consistent with previous reports suggesting that each canalicular transporter contributes to a similar degree, and together comprise approximately 90-95% of RSV biliary excretion in rat liver (Kitamura et al., 2008; Hobbs et al., 2012 (Johnson et al., 2006) .
Transporter expression and function have been reported to change over time in rat SCH. Namely, Oatp expression and function in rat SCH is decreased by 4-5 fold over days in culture (Kotani et al., 2011; Tchaparian et al., 2011) . Therefore, RSV CL Uptake likely is underestimated in rat SCH (Table 1) ; in contrast, OATP-mediated CL Uptake in human SCH appears to be maintained over days in culture (Kotani et al., 2011) . Bcrp and Mrp2 expression have been reported to increase and decrease, respectively, in rat SCH compared to liver tissue (Li et al., 2009a; Li et al., 2009b; Li et al., 2010) . Therefore, the effects of these changes may have minimal overall impact on RSV CL Bile . Available data suggest that expression of MRP3 and MRP4 in rat and human SCH may be relatively stable over days in culture (Swift et al., 2010a; Ohtsuki et al., 2012; Schaefer et al., 2012) . However, robust quantitative proteomics data for transport proteins that mediate CL BL are not yet available. In addition, the CL BL and CL Uptake parameters in Table 1 represent both active and passive components of the transport process. Given these limitations, whole liver data are needed to aid in vitro-in vivo correlation of the CL BL pathway. In addition, physiologicallybased pharmacokinetic (PBPK) modeling has been used to correlate data in human SCH to available in vivo data (Jones et al., 2012) .
Two candidate transporters that could contribute to the basolateral excretion of RSV were examined in membrane vesicles prepared from non-transfected HEK293T cells and HEK293T cells overexpressing MRP3 and MRP4. MRP3 and MRP4 transport was characterized using the prototypical substrates, E 2 17βG and DHEAS, respectively; K m estimates were similar to values previously reported (Zelcer et al., 2001; Zelcer et al., 2003) . RSV (50 µM) inhibited the MRP3-and MRP4-mediated transport of prototypical substrates to a similar extent as the prototypical pan-MRP inhibitor MK-571 (Figs. 7A and B) . Further studies were performed to evaluate the ability of MRP3 and MRP4 to transport RSV directly, showing that time-and ATP-dependent uptake in membrane vesicles prepared from MRP3-and MRP4-overexpressing cells were greater than in vesicles from non-transfected (NT) cells (Fig. 7C ).
This article has not been copyedited and formatted. The final version may differ from this version. Concentration-dependent uptake revealed that RSV was transported by MRP4 with a K m of ~21 µM.
Unbound RSV concentrations in human liver are likely to be below this K m value, despite efficient hepatic uptake and accumulation. The mean steady-state RSV maximum total plasma concentration (C max ) in humans is ~50 ng/mL (0.1 µM) following an 80 mg daily oral dose (Warwick et al., 2000; Cooper et al., 2003) . Accumulation of total RSV (Kp) in human and rat hepatocytes in vitro was ~20-fold in the present study, consistent with previous reports (Nezasa et al., 2003) , and ~20-45-fold accumulation in rat liver in vivo (Nezasa et al., 2002) , leading to estimated hepatocellular RSV concentrations of ≤ 5 µM in humans. At the present time, the contribution of other transport proteins and/or passive diffusion to RSV CL BL in SCH cannot be ruled out because specific MRP4 inhibitors have not been identified.
A novel uptake and efflux protocol was developed in SCH that revealed the significant contribution of basolateral efflux to the hepatocellular excretion of RSV in rat and human hepatocytes.
When combined with a modeling approach, this experimental paradigm can be used to elucidate the relative contribution of CL BL as well as CL Bile . RSV is a substrate for human MRP4, which likely contributes to the basolateral efflux of RSV in human liver. Importantly, MRP4-mediated efflux of RSV may be impaired due to patient-specific factors such as DDIs, genetic variation and/or disease states.
Altered function of MRP4 may lead to changes in hepatic and systemic exposure of RSV, which may impact the efficacy and/or safety of RSV. The involvement of hepatic basolateral efflux in drug disposition remains largely unrecognized except in the case of hepatically-derived drug conjugates.
Important next steps will be to assess the basolateral efflux of RSV and other drugs in whole liver to ascertain the potential role of this pathway in vivo, and the predictive capability of the current SCH method.
This article has not been copyedited and formatted. The final version may differ from this version. Parameters were altered 10-fold in either direction of the values estimated for mean control data (Table   1) , and the fold-change in the predicted model output was examined. Model output included rosuvastatin Tables   Table 1. Summary of recovered parameter estimates and residual error based on the model scheme depicted in Fig. 3 describing rosuvastatin (RSV) disposition in sandwich-cultured hepatocytes (SCH) from wild-type (WT) and Mrp2-deficient (TR -) rats in the absence (Control) or presence of GF120918, and in human SCH. SCH were treated with 0.1 and 1 µM RSV in rat SCH, and 1 µM in human SCH (see Fig. 1 .A(i) and 1.A(iii) for details of incubation conditions) and the model was fit simultaneously to all data from each preparation. 
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